[CD4+ and CD8+ T-lymphocyte counts in human immunodeficiency virus type 1 subtype A-infected patients carrying

Voprosy Virusologii
|May 12, 2010
PubMed

Insights

Certain human immunodeficiency virus type 1 (HIV-1) mutations in protease and reverse transcriptase may correlate with an improved immune response, indicated by higher CD4+ and CD8+ T-cell counts in patients.

Area of Science:

  • Virology
  • Immunology
  • Genetics

Background:

  • Human immunodeficiency virus type 1 (HIV-1) infection impacts immune cell counts, particularly CD4+ and CD8+ T-cells.
  • Understanding genetic variations in HIV-1, such as mutations in the pol gene, is crucial for analyzing disease progression and host immune response.

Purpose of the Study:

  • To investigate the association between specific genetic mutations (V77I in protease, A62V in reverse transcriptase) in HIV-1 subtype A and peripheral blood counts (CD4+, CD8+, CD4/CD8 ratio).
  • To compare immunological profiles of antiretroviral-naïve HIV-1 infected patients based on the presence or absence of these key genetic mutations.

Main Methods:

  • Analysis of 30 peripheral blood samples from antiretroviral-naïve HIV-1 subtype A infected patients.
  • Genetic analysis of the HIV-1 pol gene to identify mutations V77I and A62V.
  • Comparative immunological analysis of CD4+, CD8+ T-cell counts, and CD4/CD8 ratios between patient groups with and without identified mutations.

Main Results:

  • 19.5% of samples showed no mutations, while 75% had one or both mutations (36% had both).
  • Patients with HIV-1 variants carrying V77I and/or A62V mutations exhibited significantly increased median CD4+ (25%), CD8+ (20%), and CD4/CD8 ratios (16%) compared to those without.
  • These specific genetic mutations were correlated with elevated T-cell counts.

Conclusions:

  • The presence of V77I and/or A62V mutations in HIV-1 subtype A may be associated with a modulated immune response in infected individuals.
  • These findings suggest a potential link between specific HIV-1 genetic variants and immune system markers, warranting further investigation into their clinical significance.